{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:53:42Z","timestamp":1792760022513,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":1772,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1038\/mt.2011.201","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T14:26:58Z","timestamp":1317738418000},"page":"2178-2185","source":"Crossref","is-referenced-by-count":278,"title":["Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene \/ Allele-Specific Silencing of Mutant Huntingtin"],"prefix":"10.1016","volume":"19","author":[{"given":"Jeffrey B","family":"Carroll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C","family":"Warby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber L","family":"Southwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal N","family":"Doty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Greenlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Skotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Frank","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Freier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2011.201_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"The Huntington Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"10.1038\/mt.2011.201_bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"The Huntington Study Group","year":"2006","journal-title":"Neurology"},{"key":"10.1038\/mt.2011.201_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s002130000575","article-title":"Fluoxetine in the treatment of Huntington's disease","volume":"153","author":"De Marchi","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1038\/mt.2011.201_bib4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington's disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol Rev"},{"key":"10.1038\/mt.2011.201_bib5","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.nbd.2005.08.007","article-title":"Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models","volume":"21","author":"Graham","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1038\/mt.2011.201_bib6","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2011.201_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"10.1038\/mt.2011.201_bib8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","article-title":"Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington's disease transgenic mice","volume":"12","author":"Rodriguez-Lebron","year":"2005","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2011.201_bib9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","article-title":"Sustained effects of nonallele-specific Huntingtin silencing","volume":"65","author":"Drouet","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1038\/mt.2011.201_bib10","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2011.201_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neures.2005.06.021","article-title":"Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA","volume":"53","author":"Wang","year":"2005","journal-title":"Neurosci Res"},{"key":"10.1038\/mt.2011.201_bib12","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2011.201_bib13","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi","volume":"105","author":"McBride","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2011.201_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nchembio883","article-title":"Small molecules enhance autophagy and reduce toxicity in Huntington's disease models","volume":"3","author":"Sarkar","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1038\/mt.2011.201_bib15","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1073\/pnas.1004498107","article-title":"A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model","volume":"107","author":"Tsvetkov","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2011.201_bib16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"key":"10.1038\/mt.2011.201_bib17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ng1297-404","article-title":"Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion","volume":"17","author":"White","year":"1997","journal-title":"Nat Genet"},{"key":"10.1038\/mt.2011.201_bib18","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1038\/sj.emboj.7601445","article-title":"Huntingtin inhibits caspase-3 activation","volume":"25","author":"Zhang","year":"2006","journal-title":"EMBO J"},{"key":"10.1038\/mt.2011.201_bib19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1471-4159.2005.03605.x","article-title":"Wild-type huntingtin protects neurons from excitotoxicity","volume":"96","author":"Leavitt","year":"2006","journal-title":"J Neurochem"},{"key":"10.1038\/mt.2011.201_bib20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"},{"key":"10.1038\/mt.2011.201_bib21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/318207","article-title":"Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo","volume":"68","author":"Leavitt","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1038\/mt.2011.201_bib22","doi-asserted-by":"crossref","first-page":"14545","DOI":"10.1074\/jbc.C100044200","article-title":"Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing","volume":"276","author":"Rigamonti","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2011.201_bib23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/81593","article-title":"Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice","volume":"26","author":"Dragatsis","year":"2000","journal-title":"Nat Genet"},{"key":"10.1038\/mt.2011.201_bib24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/sj.gt.3302702","article-title":"Allele-specific RNA interference for neurological disease","volume":"13","author":"Rodriguez-Lebron","year":"2006","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2011.201_bib25","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1089\/hum.2007.116","article-title":"Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts","volume":"19","author":"van Bilsen","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2011.201_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1242\/dmm.000653","article-title":"Inactivation of Drosophila Huntingtin affects long-term adult functioning and the pathogenesis of a Huntington's disease model","volume":"2","author":"Zhang","year":"2009","journal-title":"Dis Model Mech"},{"key":"10.1038\/mt.2011.201_bib27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","article-title":"A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference","volume":"217","author":"Lombardi","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1038\/mt.2011.201_bib28","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr Biol"},{"key":"10.1038\/mt.2011.201_bib29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.chembiol.2010.10.013","article-title":"Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism","volume":"17","author":"Hu","year":"2010","journal-title":"Chem Biol"},{"key":"10.1038\/mt.2011.201_bib30","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mt.2011.201_bib31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.expneurol.2009.09.017","article-title":"Huntington's disease: silencing a brutal killer","volume":"220","author":"Pfister","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1038\/mt.2011.201_bib32","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","article-title":"Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat","volume":"49","author":"Gagnon","year":"2010","journal-title":"Biochemistry"},{"key":"10.1038\/mt.2011.201_bib33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","article-title":"CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup","volume":"84","author":"Warby","year":"2009","journal-title":"Am J Hum Genet"},{"key":"10.1038\/mt.2011.201_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1038\/mt.2011.201_bib35","doi-asserted-by":"crossref","first-page":"19954","DOI":"10.1016\/S0021-9258(19)88650-7","article-title":"Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides","volume":"267","author":"Monia","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2011.201_bib36","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2011.201_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/mol.106.025015","article-title":"Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate","volume":"71","author":"Lima","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1038\/mt.2011.201_bib38","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2011.201_bib39","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/hmg\/5.12.1875","article-title":"Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype","volume":"5","author":"Hodgson","year":"1996","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2011.201_bib40","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","article-title":"Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice","volume":"28","author":"Gray","year":"2008","journal-title":"J Neurosci"},{"key":"10.1038\/mt.2011.201_bib41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/jm801294h","article-title":"Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals","volume":"52","author":"Seth","year":"2009","journal-title":"J Med Chem"},{"key":"10.1038\/mt.2011.201_bib42","series-title":"Antisense Drug Technology. Principles, Strategies, and Applications","author":"Crooke","year":"2008"},{"key":"10.1038\/mt.2011.201_bib43","doi-asserted-by":"crossref","first-page":"21731","DOI":"10.1073\/pnas.1012153107","article-title":"Tailor-made RNAi knockdown against triplet repeat disease-causing alleles","volume":"107","author":"Takahashi","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2011.201_bib44","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nmeth.1261","article-title":"Linking SNPs to CAG repeat length in Huntington's disease patients","volume":"5","author":"Liu","year":"2008","journal-title":"Nat Methods"},{"key":"10.1038\/mt.2011.201_bib45","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrd2094","article-title":"Drug development for CNS disorders: strategies for balancing risk and reducing attrition","volume":"6","author":"Pangalos","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1038\/mt.2011.201_bib46","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1038\/mt.2011.201_bib47","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.1523\/JNEUROSCI.21-19-07608.2001","article-title":"Neurons lacking huntingtin differentially colonize brain and survive in chimeric mice","volume":"21","author":"Reiner","year":"2001","journal-title":"J Neurosci"},{"key":"10.1038\/mt.2011.201_bib48","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0896-6273(02)00615-3","article-title":"Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease","volume":"33","author":"Zeron","year":"2002","journal-title":"Neuron"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616327034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616327034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T23:01:42Z","timestamp":1639004502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616327034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1525001616327034"],"URL":"https:\/\/doi.org\/10.1038\/mt.2011.201","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}